Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 8NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 35Carcinoid Tumor 8Adenoma, Islet Cell 6Neoplasms 5Neoplasm Metastasis 3Carcinoma, Neuroendocrine 3Neuroectodermal Tumors, Primitive 2Liver Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Tuberous Sclerosis 1Thymus Neoplasms 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neuroendocrine Tumors 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Multiple Endocrine Neoplasia Type 1 1Metatropic dwarfism 1Metastatic Digestive System Neuroendocrine Tumor G1 1Lymphoma, Follicular 1Lung Neoplasms 1Kidney Neoplasms 1Glioblastoma 1Gastroenteropancreatic Neuroendocrine Tumors 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Large Cell 1

Interventions

Everolimus 2pasireotide 1Sirtuins 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy 1Drug Therapy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Liver Neoplasms × Everolimus × NET × Clear all
NCT01469572 2018-10-18

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

Emory University

Phase 1 Completed
13 enrolled
EndocrineGastrointestinalNET

Liver Neoplasms, Neuroendocrine Tumors

NCT01864070 2014-07-22

Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease

M.D. Anderson Cancer Center

Phase 1 Withdrawn
EndocrineGastrointestinalNET

Liver Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡